19 research outputs found
Algas marinas de la parte sur de la Bahia de la Paz, Baja California Sur
Volume: 59Start Page: 35End Page: 5
Avance sobre un estudio de las algas marinas de la peninsula de Yucat\ue1n
Volume: 62Start Page: 23End Page: 5
Interrelaci\uf3n entre f\uf3sforo, Bacillus subtilis y Glomus fasciculatum con la calidad en Lilium
Producci\uf3n de flores de Gerbera jamesonii cv. \u27Dream\u27 en funci\uf3n de los \ue1cidos giber\ue9lico y salic\uedlico
Inventario de \ue1rboles y arbustos con potencial ornamental en el sureste del Estado de M\ue9xico
Inventario de especies frutales y aspectos etnobot\ue1nicos en Sultepec, Estado de M\ue9xico, M\ue9xico
Platelet count and outcome in patients with acute venous thromboembolism
The relationship between platelet count and outcome in patients with acute venous thromboembolism (VTE) has not been consistently explored. RIETE is an ongoing registry of consecutive patients with acute VTE. We categorised patients as having very low- (450,000/\ub5l) platelet count at baseline, and compared their three-month outcome. As of October 2012, 43,078 patients had been enrolled in RIETE: 21,319 presenting with pulmonary embolism and 21,759 with deep-vein thrombosis. In all, 502 patients (1.2%) had very low-; 5,472 (13%) low-; 28,386 (66%) normal-; 7,157 (17%) high-; and 1,561 (3.6%) very high platelet count. During the three-month study period, the recurrence rate was: 2.8%, 2.2%, 1.8%, 2.1% and 2.2%, respectively; the rate of major bleeding: 5.8%, 2.6%, 1.7%, 2.3% and 4.6%, respectively; the rate of fatal bleeding: 2.0%, 0.9%, 0.3%, 0.5% and 1.2%, respectively; and the mortality rate: 29%, 11%, 6.5%, 8.8% and 14%, respectively. On multivariate analysis, patients with very low-, low-, high- or very high platelet count had an increased risk for major bleeding (odds ratio [OR]: 2.70, 95% confidence interval [CI]: 1.85-3.95; 1.43 [1.18-1.72]; 1.23 [1.03-1.47]; and 2.13 [1.65-2.75]) and fatal bleeding (OR: 3.70 [1.92-7.16], 2.10 [1.48-2.97], 1.29 [0.88-1.90] and 2.49 [1.49-4.15]) compared with those with normal count. In conclusion, we found a U-shaped relationship between platelet count and the three-month rate of major bleeding and fatal bleeding in patients with VTE
Outcomes in Neurosurgical Patients Who Develop Venous Thromboembolism: A Review of the RIETE Registry
OBJECTIVES:
Registro Informatizado de Enfermedad TromboEmb\uf3lica (RIETE) database was used to investigate whether neurosurgical patients with venous thromboembolism (VTE) were more likely to die of bleeding or VTE and the influence of anticoagulation on these outcomes.
METHODS:
Clinical characteristics, treatment details, and 3-month outcomes were assessed in those who developed VTE after neurosurgery.
RESULTS:
Of 40 663 patients enrolled, 392 (0.96%) had VTE in less than 60 days after neurosurgery. Most patients in the cohort (89%) received initial therapy with low-molecular-weight heparin, (33% received subtherapeutic doses). In the first week, 10 (2.6%) patients died (8 with pulmonary embolism [PE], no bleeding deaths; P = .005). After the first week, 20 (5.1%) patients died (2 with fatal bleeding, none from PE). Overall, this cohort was more likely to develop a fatal PE than a fatal bleed (8 vs 2 deaths, P = .058).
CONCLUSIONS:
Neurosurgical patients developing VTE were more likely to die from PE than from bleeding in the first week, despite anticoagulation
Fondaparinux in the initial and long-term treatment of venous thromboembolism
BACKGROUND:
Even in the absence of evidence on its long-term efficacy and safety, a number of patients with venous thromboembolism (VTE) receive long-term therapy with fondaparinux alone in everyday practice.
METHODS:
We used the Registro Informatizado de Enfermedad Tromboemb\uf3lica (RIETE) registry to compare the rate of VTE recurrences and major bleeding at 10 and 90 days in patients with and without cancer. For long-term therapy, fondaparinux was compared with vitamin K antagonists (VKA) in patients without cancer and with low-molecular-weight heparin (LMWH) in those with cancer.
RESULTS:
Of 47,378 patients recruited, 46,513 were initially treated with heparin, 865 with fondaparinux. Then, 263 patients (78 with cancer) were treated for at least 3 months with fondaparinux. After propensity-score matching, there were no differences between patients receiving initial therapy with heparin or fondaparinux. Among patients with cancer, there were no differences between fondaparinux and LMWH. Among patients without cancer, the long-term use of fondaparinux was associated with an increased risk of major bleeding (3.24 % vs. 0.95 %, p<0.05).
CONCLUSIONS:
An unexpected high rate of major bleeding was observed in non-cancer patients treated with long-term fondaparinux. Our small sample does not allow to derive relevant conclusions on the use of fondaparinux in cancer patients